Quarterly Report · 10-Q

Seaport Therapeutics, Inc.

SPTXNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 3, 2026Accepted Aug 3, 2026, 3:11 AM EDTCIK 2042347Accession 0001193125-26-329537

Company context

We are a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through our differentiated approach, we identify clinically validated mechanisms with established efficacy and safety profiles which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. We apply our proprietary GlyphTM platform to overcome those limitations and invent innovative oral therapies. Glyph is a lymphatic-targeting prodrug technology which is designed to bypass first-pass metabolism and thereby enhance a drug’s oral bioavailability and reduce side effects. This process, which we call “Glyphing,” also creates new composition of matter intellectual property. Our experienced team of industry leaders has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. We aim to develop novel, leading treatment options that will make a significant impact for patients and their families.

Current securities

SPTXNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

Seaport Therapeutics, Inc. · 10-Q · Filed 2026-08-03

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Voting Common Stock, $0.0001 par value per share

Symbol: SPTX
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: C_d35a2e77-4e31-49fc-b866-37a9f0f86ecc

Dimensions: Not supplied

Accession 000119312526329537 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.